Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRVEH: Acute hemodynamic effects of sildenafil in HFpEF and post–heart transplant patients
2013-001659-10Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sildenafil in heart failure with preserved ejection fraction (HFpEF), secondary pulmonary hypertension and heart transplantation, sponsored by UZ Leuven. Primary endpoints: Acute change in cardiac hemodynamics, Acute change in right ventricle performance and 1 more. Started May 2013; status: completed.
02
Drugs
sildenafil
03
Conditions
heart failure with preserved ejection fraction (HFpEF)secondary pulmonary hypertensionheart transplantation
Beyond the preview
Go deeper on 2013-001659-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001659-10.